Literature DB >> 7639280

Late appearance of the Philadelphia chromosome with monosomy 7 in a patient with de novo AML with trilineage myelodysplasia.

K Matsue1, T Miyamoto, M Ito, K Tsukuda.   

Abstract

We report here a patient with de novo acute myelocytic leukemia with trilineage myelodysplasia (AML/TMDS) in whom cytogenetic analysis was normal at diagnosis and in whom Philadelphia chromosome (Ph1) with monosomy 7 emerged at the terminal stage of the disease. Reverse transcription polymerse chain reaction (RT-PCTR) on the Ph1 positive specimen detected the mRNA encoding p190bcr/abl but did not detect mRNA encoding p210bcr/abl. However, mRNA encoding p190bcr/abl was not detected at diagnosis and or at relapse. These observations support the hypothesis that late-appearing Ph1 and monosomy 7 might be the result of clonal evolution during the course of leukemia, and p190bcr/abl might play a role in the terminal transformation or progression of leukemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639280     DOI: 10.1002/ajh.2830490413

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.

Authors:  Siddhartha Jaiswal; David Traver; Toshihiro Miyamoto; Koichi Akashi; Eric Lagasse; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-30       Impact factor: 11.205

2.  Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation.

Authors:  Katalin Kelemen; Komal Galani; Christopher R Conley; Patricia T Greipp
Journal:  Cancer Genet       Date:  2014-06-10

3.  Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1.

Authors:  Asako Takeuchi; Toshinori Kondo; Taizo Tasaka; Seiko Yamada; Tadashi Hirose; Hirofumi Fukuda; Risa Shimizu; Yoshiko Matsuhashi; Eisei Kondo; Hideho Wada
Journal:  Leuk Res Rep       Date:  2020-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.